A recent study led by scientists from Yale and other institutions has revealed that tirzepatide, a drug originally approved for treating type 2 diabetes, is highly effective at promoting significant weight loss in people with obesity.
This breakthrough could reshape how doctors approach both obesity and diabetes treatments.
Tirzepatide works by mimicking two hormones naturally produced in the body. These hormones not only help regulate blood sugar levels but also send signals from the gut to the brain to create a feeling of fullness.
While researchers initially noticed weight loss as a side effect in diabetes patients taking tirzepatide, they decided to explore its potential for people with obesity who do not have diabetes.
The results were impressive. Participants in the study who took the highest dose of tirzepatide lost as much as 21% of their body weight over the course of 72 weeks. For some individuals, this translated to losing 50-60 pounds.
By comparison, semaglutide, another weight-loss drug approved in recent years, achieves an average weight loss of about 15%.
Older generations of weight-loss medications typically led to only about 5% weight reduction and often came with severe side effects, making them less practical for widespread use.
In this trial, the majority of participants tolerated tirzepatide well, though some reported mild to moderate gut-related side effects, such as nausea or diarrhea. About 15% of those taking the drug dropped out of the trial, with roughly one-third of these withdrawals due to side effects.
Interestingly, 26% of participants in the placebo group also dropped out, highlighting the challenges of maintaining long-term participation in weight-loss studies.
Tirzepatide, marketed under the name Mounjaro, was approved by the U.S. Food and Drug Administration (FDA) in May 2022 for treating type 2 diabetes.
However, its potential to address obesity has generated widespread interest because of the remarkable results seen in trials.
Weight loss of 15-20% or more could have a transformative impact on medical care. For people with type 2 diabetes, this level of weight loss may lead to remission rather than just symptom management.
In an earlier study on tirzepatide for diabetes, nearly half of the participants in the early stages of the disease went into remission while taking the drug.
These findings suggest that tirzepatide could represent a new era in treating obesity, diabetes, and related health conditions.
Doctors may begin to shift their focus from solely managing blood sugar levels to helping patients achieve significant weight loss and even remission of type 2 diabetes.
The study, conducted by Dr. Robert Gabbay and colleagues, was published in the New England Journal of Medicine. This promising research provides hope for millions of people living with obesity or diabetes and could pave the way for more effective, long-lasting treatments.
If you care about weight, please read studies about diet that can treat fatty liver disease, obesity, and hop extract could reduce belly fat in overweight people.
For more information about weight, please see recent studies about how to curb your cravings for ready-to-eat foods, and results showing what you can eat to speed your metabolism up.
Copyright © 2024 Knowridge Science Report. All rights reserved.
